Geneos Therapeutics
Plymouth Meeting
About Geneos Therapeutics
Geneos is developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment. The company's technology is designed to identify relevant neoantigen targets from individual patient tumors to develop novel treatments for cancer, providing patients with tumor targeted immunotherapies to cure their disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $49.5M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2023)
- Website: geneostx.com
Industries & Categories
Biotechnology, Health Care, Oncology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/geneos-therapeutics-42686 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.